Patent law

Nicox Provides Second Quarter 2021 Business and Financial Highlights and Strategic Update

Retrieved on: 
Friday, July 16, 2021
Expense, Intellectual property law, Patent law, Royalty payment, NicOx

The number of prescriptions1 for VYZULTA in the U.S. increased by 21% in the second quarter of 2021 compared to the second quarter of 2020.

Key Points: 
  • The number of prescriptions1 for VYZULTA in the U.S. increased by 21% in the second quarter of 2021 compared to the second quarter of 2020.
  • The number of ZERVIATE U.S. prescriptions1 increased by 712% in the second quarter of 2021 over the second quarter of 2020.
  • Net revenue2 for the second quarter of 2021 was 0.7 million (including 0.6 million of net royalty payments).
  • Nicox disavows any obligation to correct or to update the information contained in analyst reports.

Barrick On Course to Achieve 2021 Production Targets

Retrieved on: 
Thursday, July 15, 2021
Expense, Intellectual property law, Patent law, Royalty payment, Barrick, Reconciliation, S&P/TSX 60, Barrick Gold

C1 cash costs per pound excludes royalties and production taxes and non-routine charges as they are not direct production costs.

Key Points: 
  • C1 cash costs per pound excludes royalties and production taxes and non-routine charges as they are not direct production costs.
  • Barrick will provide a full reconciliation of these non-GAAP financial measures when the Company reports its quarterly results on August9, 2021.
  • Barrick will provide additional discussion and analysis and other important information about its second quarter production levels and sales and associated costs when it reports actual results on August9, 2021.
  • Barrick also cautions that its 2021 guidance may be impacted by the unprecedented business and social disruption caused by the spread of Covid-19.

Verde Bio Holdings, Inc. Announces Opportunistic Divestiture of Assets

Retrieved on: 
Thursday, July 15, 2021
Expense, Intellectual property law, Patent law, Royalty payment

Verde Bio Holdings will achieve approximately 84 percent profit after holding this asset for a little more than three months.

Key Points: 
  • Verde Bio Holdings will achieve approximately 84 percent profit after holding this asset for a little more than three months.
  • In addition to the profits from sale, Verde also will receive all revenue of the assets related to production from the wells from March 1, 2021, to July 31, 2021, estimated to be approximately $80,000.
  • We are going to be opportunistic for our shareholders when the situation, such as this, necessitates it.
  • About Verde Bio Holdings, Inc.: Verde Bio Holdings, Inc. (OTC: VBHI), is a U.S. Energy Company based in Frisco, Texas, engaged in the acquisition and management of Mineral and Royalty interests in lower risk, onshore oil and gas properties within the major oil and gas plays in the U.S.

XOMA Acquires Royalty and Milestone Interest in Checkmate’s Vidutolimod (CMP-001) from Kuros Biosciences

Retrieved on: 
Thursday, July 15, 2021
Health sciences, Pharmaceutical sciences, Life sciences, Pharmaceutical industry, Expense, Intellectual property law, Patent law, Royalty payment, Medication, Gevokizumab

We were drawn to vidutolimod because of the breadth of Checkmates development activities, said Jim Neal, Chief Executive Officer at XOMA.

Key Points: 
  • We were drawn to vidutolimod because of the breadth of Checkmates development activities, said Jim Neal, Chief Executive Officer at XOMA.
  • Kuros will be eligible to receive certain sales milestone payments from XOMA based on net sales of vidutolimod.
  • XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies.
  • As of the date of this press release, all assets in XOMAs milestone and royalty portfolio, including vidutolimod, are investigational compounds.

Kaival Brands (OTCQB: KAVL): Bidi® Vapor Secures Intellectual Property Protections in China

Retrieved on: 
Thursday, July 15, 2021
Intangible assets, Monopoly, Intellectual property law, Patent law, Intellectual property, Social information processing, Bidi, Patent, The arts, Creativity

GRANT, Fla., July 15, 2021 /PRNewswire/ --Kaival Brands Innovations Group, Inc. (OTCQB: KAVL) ("Kaival Brands," the "Company," or "we"), the exclusive global distributor of products manufactured by Bidi Vapor, LLC ("Bidi Vapor"), today announced that Bidi Vapor has been granted two copyright protections and two patents by China.

Key Points: 
  • GRANT, Fla., July 15, 2021 /PRNewswire/ --Kaival Brands Innovations Group, Inc. (OTCQB: KAVL) ("Kaival Brands," the "Company," or "we"), the exclusive global distributor of products manufactured by Bidi Vapor, LLC ("Bidi Vapor"), today announced that Bidi Vapor has been granted two copyright protections and two patents by China.
  • (OTCQB: KAVL): Bidi Vapor Secures Intellectual Property Protections in China, adds to growing global IP portfolio
    The first patent, China Patent No.
  • Bidi Vapor has also secured copyrights for both the Bidi Stick and Bidi Cares names.
  • Mr. Patel went on, "These patent and copyright protections significantly bolster our global intellectual property protection portfolio we now have intellectual property protections in the United States, European Union, Australia, and China.

Volpara Health Grows Patent Collection with Recently Granted European Protection of Image Quantification

Retrieved on: 
Thursday, July 15, 2021
Patent law, Hereditary cancers, Volpara, Patent portfolio, Breast cancer

LYNNWOOD, Wash., July 15, 2021 /PRNewswire/ -- Volpara has recently been granted another patent by the European Patent Office, raising the total number of patents for the New Zealand-based health tech company to 98.

Key Points: 
  • LYNNWOOD, Wash., July 15, 2021 /PRNewswire/ -- Volpara has recently been granted another patent by the European Patent Office, raising the total number of patents for the New Zealand-based health tech company to 98.
  • This latest patent, effective across 25 European countries, outlines the Volpara method of image quantification, used in multiple instances across the Volpara Breast Health Platform product suite.
  • This patent, together with the entire Volpara patent portfolio, serves to protect all the company's products.
  • Early cancer detection is key to fulfilling the Volpara mission to eliminate late-stage breast cancer and save families from cancer.

TrippBio receives Notice of Allowance from the U.S. Patent Office for Therapeutic Treatment of COVID-19 Infections

Retrieved on: 
Thursday, July 15, 2021
Intellectual property law, Patent offices, International Searching and Preliminary Examining Authorities, Patent law, European Patent Organisation, United States Patent and Trademark Office, Patent application, Patent office, European Patent Office, Term of patent

JACKSONVILLE, Fla., July 15, 2021 /PRNewswire-PRWeb/ --TrippBio, Inc. (TrippBio), a clinical development-stage company developing antiviral treatments with an initial focus on COVID-19, today announced that the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance for patent application No.

Key Points: 
  • JACKSONVILLE, Fla., July 15, 2021 /PRNewswire-PRWeb/ --TrippBio, Inc. (TrippBio), a clinical development-stage company developing antiviral treatments with an initial focus on COVID-19, today announced that the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance for patent application No.
  • 16/875,487, and the European Patent Office (EPO) has issued a favorable opinion in a counterpart European application.
  • The availability of safe and effective treatment options can reduce the rate of hospitalizations and hopefully the long-term effects of COVID-19."
  • TrippBio is founded on the scientific research of Ralph Tripp, Ph.D., Georgia Research Alliance Chair and professor at the University of Georgia.

IPValue Management Affiliate Acquires Rights to Mitsubishi Electric’s Display Business Patent Portfolio

Retrieved on: 
Wednesday, July 14, 2021
Hardware, Data management, Other Technology, Technology, Software, Technology, Electronics, Display technology, Monopoly, Electronic engineering, Light-emitting diodes, Organic electronics, Patent law, OLED, Mitsubishi Electric, Melco, Patent portfolio

IPValue Management, Inc. (IPValue) today announced that its subsidiary, Trivale Technologies, LLC (Trivale), has acquired over 1,200 patents and applications from the display business unit of Mitsubishi Electric (MELCO).

Key Points: 
  • IPValue Management, Inc. (IPValue) today announced that its subsidiary, Trivale Technologies, LLC (Trivale), has acquired over 1,200 patents and applications from the display business unit of Mitsubishi Electric (MELCO).
  • IPValue focuses its patent licensing programs on extensive portfolios from major enterprise innovators like MELCO.
  • This portfolio is the result of over two decades of R&D by the display business unit and encompasses a broad range of LCD, OLED, and other technologies for high value display products.
  • Since inception in 2001, IPValue has generated over $2B in cash from patent licenses, resulting in $1B to its partners.

LONGi has achieved several successes in patent dispute against Hanwha Q-Cells

Retrieved on: 
Wednesday, July 14, 2021
Intellectual property law, Patent law, United States Patent and Trademark Office, United States patent law, Patent, Versata Development Group, Inc. v. SAP America, Inc., Patent troll

This once again confirmed that LONGi's products did not infringe on Hanwha Q-Cells' US Patent 9,893,215B2, which fully consistent with LONGi's understanding of this patent.

Key Points: 
  • This once again confirmed that LONGi's products did not infringe on Hanwha Q-Cells' US Patent 9,893,215B2, which fully consistent with LONGi's understanding of this patent.
  • It follows LONGi's earlier success in invalidating this patent in another IPR proceeding of Patent Trial and Appeal Board of the U.S. Patent and Trademark Office (USPTO).
  • At the same time, LONGi firmly believes that the relevant products do not infringe the European patent EP2220689B1 within one patent family.
  • The USPTO agreed with LONGi that all of the claims in Hanwha Q-Cells' patent do not fulfill several legal requirements and are unpatentable.

LONGi has achieved several successes in patent dispute against Hanwha Q-Cells

Retrieved on: 
Wednesday, July 14, 2021
Intellectual property law, Patent law, United States Patent and Trademark Office, United States patent law, Patent, Versata Development Group, Inc. v. SAP America, Inc., Patent troll

This once again confirmed that LONGi's products did not infringe on Hanwha Q-Cells' US Patent 9,893,215B2, which fully consistent with LONGi's understanding of this patent.

Key Points: 
  • This once again confirmed that LONGi's products did not infringe on Hanwha Q-Cells' US Patent 9,893,215B2, which fully consistent with LONGi's understanding of this patent.
  • It follows LONGi's earlier success in invalidating this patent in another IPR proceeding of Patent Trial and Appeal Board of the U.S. Patent and Trademark Office (USPTO).
  • At the same time, LONGi firmly believes that the relevant products do not infringe the European patent EP2220689B1 within one patent family.
  • The USPTO agreed with LONGi that all of the claims in Hanwha Q-Cells' patent do not fulfill several legal requirements and are unpatentable.